(Q42466216)

1 November 2017

1 reference

title

Letrozole. A review of its use in postmenopausal women with advanced breast cancer (English)

1 reference

1 November 2017

H M Lamb

1

1 reference

1 November 2017

J C Adkins

series ordinal

2

1 reference

1 November 2017

language of work or name

1 reference

1 December 1998

1 reference

1 November 2017

1 reference

1 November 2017

volume

56

1 reference

1 November 2017

issue

6

1 reference

1 November 2017

page(s)

1125-1140

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199856060-00020

1 November 2017

exact match

0 references

cites work

Aromatase inhibitor development for treatment of breast cancer

1 reference

12 December 2020

Pivotal trials of letrozole: a new aromatase inhibitor

1 reference

12 December 2020

Aromatase inhibition for breast cancer treatment

1 reference

12 December 2020

A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma

1 reference

12 December 2020

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

1 reference

12 December 2020

An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cells

1 reference

12 December 2020

Future uses for aromatase inhibitors in breast cancer

1 reference

12 December 2020

An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients

1 reference

12 December 2020

1 reference

12 December 2020

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

1 reference

12 December 2020

Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.

1 reference

12 December 2020

Estrogen synthesis inhibitors: from "off the rack" to haute couture

1 reference

12 December 2020

Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake

1 reference

12 December 2020

Absolute bioavailability of letrozole in healthy postmenopausal women

1 reference

12 December 2020

Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer

1 reference

12 December 2020

Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

12 December 2020

New endocrine therapies for breast cancer

1 reference

12 December 2020

Aromatase activity in primary and metastatic human breast cancer

1 reference

12 December 2020

Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer

1 reference

12 December 2020

Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study

1 reference

12 December 2020

Regulation of aromatase activity within the breast

1 reference

12 December 2020

Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.

1 reference

12 December 2020

Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole

1 reference

12 December 2020

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

1 reference

12 December 2020

The control and biological importance of intratumoural aromatase in breast cancer

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women

1 reference

12 December 2020

The importance of local synthesis of estrogen within the breast

1 reference

12 December 2020

Endocrine therapies of breast cancer

1 reference

12 December 2020

Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration.

1 reference

12 December 2020

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

1 reference

12 December 2020

New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity

1 reference

12 December 2020

The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511

1 reference

12 December 2020

10.2165/00003495-199856060-00020

Identifiers

DOI

1 reference

Dimensions Publication ID

1 November 2017

1014893759

0 references

1 reference